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Abstract: 
A new naphtylbiliverdin compound has been synthesized which offers intense absorption with the 
photodynamic therapy window (600 nm – 850 nm). The compound has been characterized by proton 
NMR, high resolution electrospray mass spectrometry, elemental analysis, and UV/vis spectroscopy. 
Coordination of four ruthenium(II) polypyridyl complexes was accomplished by standard procedures. 
The new tetra-ruthenated naphthylbiliverdin was characterized by elemental analysis. Cyclic 
voltammetry measurements reveal that all four ruthenium moieties are coordinated to the pyridyl 
groups of the biliverdin compound. The intense metal to ligand charge transfer (MLCT) bands of the 
peripheral ruthenium groups overshadow the absorption due to the biliverdin compound; therefore, 
spectroelectrochemical studies were conducted to show that the low energy absorption of the 
naphthylbiliverdin compound is unaffected by coordination to the ruthenium groups. DNA 
photocleavage studies were performed by irradiating samples containing plasmid DNA and the 
ruthenated compound, filtering out high energy light. Gel electrophoresis studies indicate that the 
compound is capable of photonicking the plasmid DNA when irradiated with light. 
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Introduction 
 
I. Photodynamic Therapy 
 
Photodynamic therapy is the use of light, molecular oxygen, and a 
photosensitizer to destroy tumor cells.  In 1900, Oskar Raab discovered 
photodynamic therapy
1
 when he used acridine orange and light to destroy 
living organisms.  This therapeutic use of light was further investigated and it 
was found by Policard that fluorescence was more targeted toward tumor cells 
than normal healthy tissue.
2
  Gaining this insight led to development of 
photodynamic agents which were used to treat bacterial infections
3
 and 
inflammation.
4
  Tumor specificity of photodynamic therapy agents also led to 
treatment of bladder cancers, brain cancers, breast metastases, skin cancers, 
gynecological malignancies, colorectal cancers, thoracic malignancies, oral 
cancers, and neck cancers.
5
 
For reasons not completely understood, photodynamic therapy causes 
immune system suppression along with the cancer cell death.
6
  Korbelik
7
 has 
studied the mechanism associated with immune system suppression associated 
with PDT and has found that tissues which are treated in PDT release large 
amounts of cell debris, inflammatory signals, cytokines, and chemo-tactic 
agents which cause the tissue to secrete immunosuppressive signals leading to 
the immuno-depression in the cell.   
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II. Mechanisms 
As stated earlier, photodynamic therapy is the use of therapeutic light, 
molecular oxygen, and a photosensitizer to destroy cancerous cells in a 
multitude of different diseases.  This route of treatment is a more targeted and 
less invasive approach than other methods such as surgery or chemotherapy 
and comes with little side effects.  There are two different mechanisms that 
explain the destruction of tumor cells in photodynamic therapy, both which 
start by excitation of a photosensitizer with light.
8
 
Excitation of the photosensitizer causes promotion of an electron to a 
higher energy state.  In the Type I mechanism, the excited photosensitizer 
goes on to react with molecular oxygen to give the superoxide radical 
(illustrated in Scheme 1) which can go on to form hydroxyl radicals (OH
●
) 
which are extremely toxic and lethal to the cell.  The Type I mechanism is 
dependent on the target substrate concentration in the cell.  A reaction which 
is less likely to occur but is thought to happen in anoxic environments is when 
the excited photosensitizer reacts directly with an organic substrate by 
electron exchange.  This electron exchange, usually with guanine of the DNA 
which is most easily oxidized, fills the hole on the photosensitizer which was 
left empty during excitation.
9
  Oxidation of the guanine causes destruction of 
the DNA thus promoting apoptosis. 
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       Scheme 1: Photodynamic Therapy Mechanisms 
 
 
 
 
 
 
 
 
 
 
 
The Type II mechanism also involves excitation of a photosensitizer with 
light but it transfers energy to the ground state of oxygen changing triplet state 
oxygen into the more reactive singlet state oxygen (Scheme 1).  Oxygen in the 
singlet state is now able to go on and destroy cellular function by reacting 
with various portions of the cell.
10
  Oxygen is unique in that it has low lying 
excited states and the energy required to transition into the excited state is also 
low.
11
  This Type II mechanism is thought to be the main mechanism of 
photodynamic therapy in cells and is characterized by a dependence on 
oxygen concentration within the cell.
12
 
The first compound used as a photosensitizer for photodynamic therapy 
was a hematoporphyrin derivative which was later purified and is marketed as 
Photofrin®. It has been authorized to treat lung and esophageal cancers along 
with dysplasia.
13
  Photofrin®, Figure 1, a purified version of the 
hematoporphyrin derivative was first discovered in the 1970’s. It’s use as a 
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photosensitizer in PDT is to create singlet state oxygen from triplet state 
oxygen upon photoexcitation in the visible region of the spectrum.
14
  
Unfortunately, Photofrin® is not efficient at forming singlet oxygen and 
therefore patients have to stay out of the light for several hours after treatment. 
In addition Photofrin® is extremely difficult to purify.
15-18   
 
 
 
 
 
 
 
Figure 1: Photofrin® 
III. Porphyrins as Photosensitizers 
Porphyrins have, for many years, been studied for their capabilities as 
PDT agents due to their planar aromatic structure, photophysical properties, 
and straight forward synthesis.
19-23
  The general synthesis of a porphyrin and a 
metalloporphyrin requires the reaction of a pyrrole and an aldehyde, shown 
below in Figure 2, and then further purification using column 
chromatography.  The spectroscopic properties of these compounds are 
characterized by intense absorptions near 400 nm (the Soret band) with molar 
absorptivities in the hundreds of thousands and less intense Q-bands ranging 
from 500 nm to 700 nm.  For the greatest penetration of light through human 
tissue there exists a photodynamic therapy window which lies between 600 
nm and 850 nm; since the lower energy Q-bands of the porphyrin are located 
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near 650 nm these are the bands of interest for PDT.  Unfortunately, due to the 
relatively low molar absorptivities of these Q-bands they suffer from the same 
problem as Photofrin and are not able to efficiently generate singlet oxygen 
within the PDT window. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Synthesis of Porphyrin and Metalloporphyrin 
 
Another issue associated with porphyrins is their lack of water solubility.  
Cationic porphyrins have been studied to try and solve this issue because they 
tend to be more water soluble and also have strong electrostatic interactions 
with the negatively charged DNA backbone.
24 
 Other examples of 
synthetically modified porphyrins include halogenated porphyrins which have 
extend excited state lifetimes resulting in greater singlet oxygen formation.
25-
28
  It was found that by covalently binding halogens to the meso-positions, the 
excited state lifetime is significantly longer than in un-halogenated analogs.
25
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Ruthenium complexes containing polypyridyl ligands have also been 
synthesized for the Metal to Ligand Charge Transfer (MLCT) state of the 
ruthenium that is proven to lead to formation of reactive oxygen species which 
have the ability to cleave supercoiled DNA.
29   
Our choice to use ruthenium 
polypyridyl moieties as pendant groups stems from the initial work of Araki, 
Toma and coworkers, as seen below in Figure 3. 
 
               Figure 3: Structural representation of [TPyP{Ru(bipy)2Cl}4]
4+
 complex, TRP.
30 
 
Recently, a number of groups have explored the synthetic possibilities of 
shifting the Soret band further into the visible region of the spectrum. This has 
been accomplished, in large part, by extending the conjugation of the pyrrole 
groups leading to porphyrins with Soret bands shifted to 550 nm and greater.
31
  
Unfortunately, due to synthetic limitations the majority of these new 
porphyrins are not water soluble, limiting their applications. 
Oxidation of porphyrins to biliverdins has recently received a great deal of 
attention. These linear tetrapyrroles can play important roles in molecular 
electronics and liquid crystals.
32
 Numerous methods have been used to 
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facilitate the formation of biliverdins from porphyrins such as photochemical 
oxidation, chemical oxidation, and coupled oxidation.
33-35
  In biological 
systems degradation of heme occurs in the spleen by the enzyme heme 
oxygenase converting the heme to biliverdin.  
In our attempt to make a π-extended naphtylporphyrin containing 
peripheral coordination sites we have unexpectedly isolated a new type of 
biliverdin with long wave excitation and fluorescence properties. These 
complexes have been investigated for their electrochemical and spectroscopic 
properties. In addition, insertion of transition metal ions into the porphyrin 
core resulted in catalytic and small molecule detection applications. 
Irradiation of solutions of the free base tetra-ruthenated porphyrin and plasmid 
DNA resulted in single strand breaks.
30
  Since this work, numerous ruthenated 
porphyrin complexes have been studied as potential photodynamic therapy 
agents.  Herein we present our attempt to create a tetra-pyridyl porphyrin with 
extended conjugation of the pyrrole units capable of coordinating four 
[Ru(bpy)2Cl]
+
 moieties. 
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Experimental  
 
I. Materials 
1-nitronapthalene (Acros), tetrahydrofuran (Acros), ethyl 
isocyanoacetate (Acros), phosphazene base (Aldrich), dichloromethane 
(VWR), sodium sulfate (Fisher), silica gel (Fisher), methanol (Fisher), acetone 
(Fisher), toluene (Fisher), potassium hydroxide (Fisher), ethylene glycol 
(Acros), hydrazine (Aldrich), propionic acid (Acros), ammonium hydroxide 
(Acros), chloroform (Fisher), glacial acetic acid (Fisher), acetonitrile (VWR), 
used for electrochemistry, and tetra-n-butyl ammonium hexafluorophosphate 
(Bu4NPF6, used as supporting electrolyte for electrochemistry, Acros) were 
used without further purification. cis-Ru(bipy)2Cl2 was synthesized as 
previously described.
36
  The plasmid, pUC18, was obtained from Buyou 
Biolabs. Electrophoresis-grade low EEO agarose, tris base, sodium chloride 
and boric acid were obtained from Fisher. Ethidium bromide was obtained 
from EM Science. The spectroscopic titration was carried out at room 
temperature in the buffer (5 mM Tris-HCl, 0.1 mM NaCl, pH 7.2). 
Concentration of calf thymus DNA (Sigma) solution used in the titrations was 
determined spectrophotometrically using the extinction coefficient 6600 M
-1
 
cm-1 at 260 nm.
37
  The photocleavage studies were carried out in room 
temperature using buffer (0.44 M Tris base, 0.44 M Boric acid). All aqueous 
solutions were prepared using doubly distilled water. Elemental analysis was 
performed by Atlantic Microlab, Norcross, Ga. High resolution electrospray 
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mass spectrometry was performed by the Ohio State mass spectrometry and 
proteomics facility, Columbus, OH. 
 
II. Synthesis 
Naphthylpyrrole Ester  
The naphthylpyrrole ester was synthesized as previously described.
38
  To a 
solution of 2.30 g (13.3 mmol) of 1-Nitronapthalene in 100 mL of dry THF was 
added 2.00 g (17.7 mmol) of ethyl isocyanoacetate and 4.20 mL (13.7 mmol) of 
phosphazene base. The solution was refluxed overnight upon which, after cooling 
to room temperature, the solution was diluted with dichloromethane, washed with 
water, and dried over sodium sulfate. After removing the solvent under reduced 
pressure the brown powder was chromatographed on silica gel using 
dichloromethane as eluent. After the first orange band was collected the solvent 
was switched to 1% methanol to collect the product as a pale yellow compound. 
Recrystallization from hot toluene gave the final peach colored product.  
Naphthylpyrrole   
To a solution of 1.5 grams of potassium hydroxide in 20 mL of ethylene 
glycol was added 0.43 g (1.8 mmol) of the naphthylpyrrole ethylester. The 
solution was purged with nitrogen for 20 min and 10 drops of hydrazine was 
added. After reflux for 30 min under nitrogen the solution was added to an 
ice/water mixture resulting in a gray precipitate. The precipitate was filtered, 
washed with water and air dried overnight to give a yield of 0.22 g.  
Naphthylbiliverdin  
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A 75 mL solution of propionic acid containing 2.7 grams (0.016 moles) of 
naphthylpyrrole and 1.7 g (0.016 moles) of 4-pyridine carboxaldehyde was 
refluxed for1 h. After cooling to room temperature, 50.0 mL of methanol was 
added. This was then neutralized with 150 mL of 50:50 methanol/NH4OH 
solution. The precipitate was filtered and air dried overnight. Chromatography 
was performed using silica gel with choloform followed by a 1% methanol/CHCl3 
to collect the first band. This was followed by a 2% methanol/CHCl3 to collect the 
second band and then finally a 5% methanol solution to collect the last purple 
band yielding 75 mg of product. Anal. Calc. for C72H42N8O2∙4H2O: C, 77.06; H, 
4.40; N, 9.99, Found: C, 76.74; H, 4.10; N, 9.80; TOF MS ES+ m/z 1052 
(M+H
+
). 
Tetra-ruthenated naphthylbiliverdin 
Under a nitrogen atmosphere 20 mg (0.02 mmol) of naphthylbiliverdin 
and 38 mg (0.08 mmol) of cis-Ru(bipy)2Cl2 were refluxed in 15 mL of glacial 
acetic acid for 45 minutes. The solvent was removed and approximately 5 mL of 
methanol was added and refluxed under N2 gas for an additional 30 minutes. The 
solution was added drop-wise to an aqueous saturated ammonium 
hexafluorophosphate solution, the precipitate was filtered, washed with water, and 
air dried to yield 56 mg. Anal. Calc. for C152H106N24O2Cl4P4F24Ru4∙8H2O: C, 
51.12; H, 3.44; N, 9.41; F, 12.77, Found: C, 51.39; H, 3.28; N, 9.32; F, 12.38. 
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III. Measurements 
Electronic Spectroscopy 
 UV/Vis spectra were recorded for all three compounds at room 
temperature using an HP-8453 photodiode array spectrophotometer with 2 nm 
resolution.  Samples were run in acetonitrile in 1 cm quartz cuvettes. 
Electrochemistry 
 Solution cyclic voltammograms were recorded using a one-compartment, 
three electrode cell (model 630A Electrochemical analyzer from CH-Instruments) 
equipped with a platinum wire auxiliary electrode. The working electrode was a 
2.0 mm diameter glassy carbon electrode from CH-Instruments. The working 
electrode was polished first using 0.30  followed by 0.05  alumina polish 
(Buehler), then sonicated for 20 sec. and tapped dry with a kimwipe prior to use. 
Potentials were referenced to a silver/silver chloride electrode(Ag/AgCl).  The 
supporting electrolyte was 0.1 M Bu4NPF6 and the measurements were made in 
extra dry acetonitrile.   
Spectroelectrochemistry 
 A spectroelectrochemical analysis of the ruthenated porphyrin was 
conducted according to a previously described method with a locally constructed 
H-cell which uses a quartz cuvette as the working compartment.
39
  The working 
and auxillary compartments of the H-cell were separated by a glass frit. The 
potetials were referenced versus a Ag/AgCl electrode, a platinum wire served as 
the auxillary electrode and a high surface area platinum mesh served as the 
working electrode. The solution contained 0.1 M Bu4NPF6 as the supporting 
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electrolyte and all measurements were made in acetonitrile.  A CH-Instruments 
630A electrochemical analyzer controlled the electrolysis potential. 
DNA Titrations 
 DNA titrations of the three compounds were conducted using an HP-8453 
photodiode array spectrophotometer with 2 nm resolution. A 1 cm quartz cuvette 
was filled with 3 mL of the ruthenated compound for initial analysis under 
UV/Vis and subsequent 5 L aliquots of calf thymus DNA in buffer (5 mM Tris-
HCl, 0.1 mM NaCl, pH 7.2) were added up to 100 L of DNA. 
 Photocleavage 
 Photocleavage of the ruthenated compound was conducted using buffer 
(0.4 M Tris base, 0.4 M Boric acid) combined with pUC18 at a ratio of 10:1 bp: 
complex in a 500 L quartz cuvette. The cuvette was irradiated under visible light 
using a 420 nm cutoff filter with a 300 W mercury arc lamp. At 10, 20, 30, 40, 50, 
60, 70, and 80 minute time intervals samples of the solutions were removed and 
run on a 0.8% agarose gel by applying 226 V for 45 minutes in approximately 500 
mL of Tris buffer solution. The gels were stained with ethidium bromide and 
photographed using UV illumination. 
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Results and Discussion 
 
I. Synthesis and characterization 
To simultaneously allow for coordination of ruthenium polypyridyl moieties 
and incorporate water solubility to a highly conjugated porphyrin, 4-pyridine 
carboxaldehyde was chosen for the meso-substituent. Understanding that the 
Lindsey method
40
 has limited success when heterocyclic aldehydes are used
41-43 
we opted to use the Adler-Longo
44
 synthetic route. Since this method typically 
results in low yields it was necessary to use larger quantities of starting reagents. 
Gram quantities of naphtha[1,2-c]pyrrole
41-43 
and 4-pyridine carboxaldehyde were 
subsequently refluxed in propionic acid and neutralized with an ammonium 
hydroxide/methanol solution. Further purification yielded a bright purple powder 
with an intense band at ca. 560 nm in the electronic absorption spectrum. We 
were puzzled however by the absence of Q-bands. Further analysis of the 
compound using soft ionization mass spectroscopy (TOF MS ES+) gave an [M-
H]
+
 of 1052. The MS data along with elemental analysis and 
1
H NMR led us to 
the proposed structure given in Scheme 2. 
Scheme 2. Synthesis of naphthylbiliverdin. 
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Although not the target porphyrin we had anticipated, we were able to 
successfully coordinate [Ru(bpy)2Cl]
+
 to the pyridyl nitrogens to give complex I 
seen in Figure 4 below. 
 
Figure 4: [complex I] 
Electronic absorption spectra of naphthylbiliverdin and its ruthenated 
analog (I) was run in acetonitrile solutions, Fig. 5. A broad absorption band with 
max of 560 nm is observed for biliverdin compound with a molar absorptivity of 
ca. 34,000 M
-1
cm
-1
, blue line Fig. 5, associated with -* transitions. 
 
Figure 5. UV/vis spectra of naphthylbiliverdin, blue line, and I, red line, in acetonitrile. 
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The ruthenated complex (I), red line Fig. 5, displays an intense absorption 
band at 295 nm associated with -* transitions of the bipyridyl groups. Two less 
intense bands at 366 nm and 493 nm are attributed to the Ru(d)-bpy(*) metal to 
ligand charge transfer (MLCT) transitions. A slight shoulder red-shifted from the 
493 nm absorption band is believed to be the result of the underlying -* 
transitions of biliverdin core.  Solution phase cyclic voltammetry (CV) in dry 
acetonitrile containing TBAPF6 as supporting electrolyte was performed using a 
three electrode system with a glassy carbon working electrode. Figure 6 illustrates 
the results of this study where Fig. 6A represents the cyclic voltammogram of 
TPyTNP and Fig. 6B represents the cyclic voltammogram of complex I.  
When the TPyTNP solution is cycled in the cathodic direction there is an 
irreversible reduction process at -0.74 V versus Ag/AgCl which is due to 
reduction of the ligand, further cathodic scanning led to a sharp irreversible 
reduction wave nearly off scale (not shown). It is unclear what this wave 
represents, possibly surface polymerization. In the anodic direction there is 
evidence for an irreversible oxidation wave at approximately 1.40 V versus 
Ag/AgCl. Solution cyclic voltammetry of complex I, Fig. 6B, shows two 
irreversible reduction waves at -0.28 V and -0.69 V versus Ag/AgCl and a 
reversible redox couple with E1/2 = 0.87 V (E = 70 mV) associated with the 
Ru(III/II) couple. This represents a shift of ca. 0.40 V when compared to the 
Ru(bpy)2Cl2 starting material indicative of the stabilization of the t2g orbitals of 
Ru upon replacing a -donor ligand (Cl-) with a -acceptor ligand (pyridine) thus 
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indicating that the ruthenium is indeed coordinated to the pyridyl groups of 
TPyTNP.  
 
Figure 6. Cyclic voltammograms of TPyTNP, A, and complex I, B, in 0.1 M 
TBAPF6/acetonitrile at room temperature.  = 100 mV/s, N2 atmosphere. 
 
To help determine if the absorption band observed for TPyTNP at ca. 560 
nm is present in the ruthenated complex (I) spectroelectrochemistry was 
performed. Electrolysis of a solution of I at a potential of 1.20 V versus Ag/AgCl 
oxidized the Ru(II) to Ru(III) thus decreasing the Ru(d) to bpy(*) MLCT 
transition without effecting the TPyTNP. Figure 7 illustrates the spectroscopic 
results of the oxidative electrolysis of a solution of I in acetonitrile solution. As 
the potential is applied the MLCT transition at 493 nm begins to decrease. A new 
band at 595 nm begins to appear, associated with the absorption of the TPyTNP 
ligand. The new transition is shifted to the red by 35 nm compared to the free 
TPyTNP absorption band, Fig. 5 blue line. This is in agreement with the positive 
shift observed in the reduction of TPyTNP of complex I from -0.74 V for the free 
TPyTNP (Fig. 6A) to -0.69 V for complex I (Fig. 6B) resulting from stabilization 
of the TPyTNP * orbitals upon coordination of the Ru(II) moiety. 
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Figure 7. Spectroelectrochemistry complex I in 0.1 M TBAPF6 acetonitrile at room 
temperature. Electrolysis performed at 1.20 V vs. Ag/AgCl. 
 
 
In addition an isosbestic point at ca. 665 nm is observed with an increase 
of a broad shoulder at 745 nm indicative of only two species in solution (i.e. 
Ru(II) complex I and Ru(III) complex I). 
II. DNA binding 
To determine quantitatively a binding constant for the interaction of complex I 
with DNA absorption titrations were used. Aqueous solutions of constant 
[complex I] were titrated with pH 7 buffered solutions of calf thymus (CT) DNA, 
the titrations were run in triplicate. Figure 8 illustrates the effects of additions of 
CT-DNA on the absorbance of the MLCT transition at 493 nm for complex I. The 
MLCT transition decreases as the concentration of CT-DNA increases indicating 
an interaction between complex I and CT-DNA.  The intrinsic binding constant 
Kb for the CT-DNA complex I interaction was determined from equation 1:
45
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[DNA]/(a-f) = [DNA]/(b-f) + 1/Kb(b-f)         eq. 1 
where a = absorbance/[complex I], b and f are the extinction coefficients for the 
fully bound and free form of complex I respectively. A linear fit of the plot (inset 
Fig.8) of [DNA]/(a-f) versus [DNA] gives a slope of 1/(b-f) and an intercept of 
1/Kb(b-f). A value of Kb = 6.0 x 10
5
 M
-1
 was determined by this method. The 
magnitude of Kb suggest and intercalative process for the binding of complex I 
with DNA.
46 
 
Figure 8. Absorption spectra of complex I in the presence of increasing amounts of CT-
DNA [Complex I] = 20 M, [DNA] = 0 –3.1M. 
 
I. DNA photoreactions 
When buffered, pH 7, solutions of circular plasmid DNA (pUC18) containing 
complex I, in a ratio of 10:1 bp:complex I, are irradiated with a 300 W mercury 
arc lamp, filtered to allow only light of 420 nm and higher to penetrate the 
solution, the supercoiled DNA is converted to nicked circular DNA, Figure 9.  
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Figure 9. Gel electrophoresis of circular plasmid DNA (pUC18) in the presence of 
complex I (lanes 2-10) and without complex I (lane 1) irradiated with a 300 W mercury 
arc lamp filtered to allow only light of 420 nm and higher to penetrate. Samples taken at 
10 min intervals. 
 
Lane 1 represents the plasmid DNA without complex.  Lane 2 represents a 
solution of plasmid DNA and complex I prior to irradiation.  Lanes 3-10 represent 
plamid DNA and complex I with irradiation; samples were taken at 10 minute 
intervals. Lane 3 indicates that after only 10 min of irradiation the majority of the 
plasmid DNA has been photonicked. After 30 min all of the plasmid DNA has 
been photonicked, lane 5 Fig. 9. Further irradiation does not result in complete 
photocleavage of the plasmid DNA. Similar experiments were run with a 550 nm 
filter, allowing only light of 550 nm or higher to penetrate the solution, with no 
effect on the plasmid DNA. We had expected that due to the intense absorption of 
the TPyTNP ligand at greater than 550 nm photonicking of the plasmid DNA 
would occur. 
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Conclusion 
In this study, a tetra-ruthenated billiverdin was synthesized and characterized.  
Synthesis of the complex was done using the Adler-Longo process and subsequent 
coordination of ruthenium complexes was completed using previously synthesized cis-
Ru(bipy)2Cl2.  This newly created tetra-ruthenated billiverdin was characterized and the 
structure was verified through UV/VIS spectroscopy, cyclic voltametry, electrolysis, and 
mass spectrometry.  DNA titration studies indicate that this compound is able to bind to 
DNA through intercalation with the DNA backbone.  Photocleavage studies of this 
compound indicate that through photonicking, the compound is able to effectively cleave 
the DNA which suggests the potential of the compound as candidate for cell destruction. 
 Further direction of this research will include re-synthesis of the billiverdin 
complex for verification of the methods used.  The complex will also be analyzed for 
verification of characterization.  Once the billiverdin structure is confirmed, it will again 
be tested for it’s ability to bind and then cleave DNA.  The hypothesis for this experiment 
using the billiverdin without the ruthenium groups is that the billiverdin will be able to 
more effectively cleave DNA within the photodynamic window. 
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